HopeStage
Back to all studies
Active Not RecruitingNCT07693608

An Open-Label Tirzepatide Trial for Comorbid Obesity and Addiction

Medication studyAges 18–65United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
DallasSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: August 19, 2026
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
45
Sponsor
University of Texas Southwestern Medical Center
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT07693608
Official title
Show the full official title

An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder Using fMRI to Identify Novel Neural Biomarkers

Recruitment & locations

Not recruiting

Dallas

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Texas Southwestern Medical Center, a university.

Does this study involve medication?

Yes. The study involves medication, including Tirzepatide.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies